Introduction
Small-cell carcinoma of the lung accounts for 18% of lung cancers, but may also arise from extra-pulmonary sites. This report is the first we identified in the literature of small-cell carcinoma of the seminal vesicle. Of particular importance is the long term response achieved with chemotherapy.
Case report
In February, 1988, a 28-year-old man developed pelvic discomfort and was found to have a large pelvic mass arising from the seminal vesicle. Electron microscopy of a biopsy showed neurosecretory granules and special stains also confirmed a small-cell carcinoma. Staging studies showed no evidence of tumor outside the pelvis.
The patient was treated with four cycles of cyclophosphamide/doxorubicin/vincristine. A partial response was confirmed at laparotomy, but he still had biopsy proven small-cell carcinoma arising from the seminal vesicle, clearly separate from the prostate.
Because of residual disease, the patient received two cycles of BCNU/cisplatin/etoposide. He achieved a clinical complete remission and completed chemotherapy in November, 1988. He did well until February, 1991, when he was found to have biopsy proven recurrence in a periaortic lymph node. The patient declined additional therapy.
By September, 1991, the patient was having increasing symptoms referable to an enlarging pelvic mass. He declined reinstitution of intravenous chemotherapy, but he did agree to treatment with etoposide, 50 mg orally twice daily for three weeks, repeated monthly. Despite poor compliance, the patient again showed a very dramatic symptomatic and radiographic response to chemotherapy.
By January, 1994, the patient's pelvic CT scan was worse. He failed to respond to additional chemotherapy, including cyclophosphamide/doxorubicin/vincristine; mesna/ifosfamide; and paclitaxel, sequentially. He died in January, 1995, of widespread metastatic disease.
Discussion
Cancers of the seminal vesicle are exceptionally rare, with Benson et al. reporting only 37 cases in the literature in 1984, none of which were small-cell cancers [1] . Small-cell cancer of the prostate has been reported previously, although this is relatively unusual [2] [3] [4] . Tetu et al. [2] , reported only 20 cases of small-cell carcinoma of the prostate seen at the M.D. Anderson Hospital over a 23-year period, and Moore et al. described only 50 patients in the world's literature through 1992 [4] .
The prognosis in patients with small-cell carcinoma of the prostate is universally poor. After the diagnosis of small-cell carcinoma in the M.D. Anderson study, the median survival was 15 months, with only one patient living 18 months, and that patient was terminally ill at the time of the report [2] . Similarly, Ro et al. reported a median survival of seven months in patients with small-cell carcinoma of the prostate [5] .
There are reports of patients with small-cell carcinoma of the prostate responding to chemotherapy. Hindson et al. reported one patient with small-cell carcinoma of the prostate who had a transient complete remission with combination chemotherapy, although he died within eight months of presentation [3] . The patient described in this report survived for nearly seven years after the original diagnosis of small-cell carcinoma of the seminal vesicle, a survival not previously reported in the literature. This preliminary report should motivate additional studies as to the role of combination chemotherapy in patients with extra-pulmonary small-cell cancer, even with localized disease.
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Is acute dyspnoea a rare side effect of vinorelbine?
Raderer et al. recently observed 16 cases of acute dyspnoea during chemotherapy with vinorelbine [1] , and Hohneker, analysing three North American multicenter trials, reported seven cases of acute grade III dyspnoea [2] .
We have encountered six cases of acute dyspnoea recently which were also probably vinorelbine-related. Since 1993 we have treated 78 non-small-cell lung cancer patients and 14 advanced breast cancer patients in a total of 632 courses of vinorelbine 30 mg/m 2 , for a median of eight courses per patient. Acute grade IV dyspnoea (according to the W.H.O. scale) was observed in six patients (6.5%), three of whom had lung cancer and three breast cancer.
None of the lung cancer patients had previously received chemotherapy, while all of the breast cancer patients were given vinorelbine as second-line therapy after progression following anthracycline therapy.
Acute dyspnoea occurred in two patients after the 4th course of vinorelbine and in the others after the 1st, 3rd, 8th and 10th courses. All of the patients had to be hospitalized, and in all of them clinical presentation, electrocardiogram and chest X-rays were suggestive of extensive interstitial and alveolar infiltrates with acute heart failure. They were all discharged a few days after the onset of the respiratory manifestations, having been treated with oxygen supplementation, intravenous glucocorticoids, diuretics and nitrates.
Acute dyspnoea is a rare side effect of vinorelbine [1, 2] . Hohneker, analysing three multicentric trials comprising 327 patients treated with vinorelbine, reported 17 cases of acute dyspnoea, 7 of grade III and none of grade IV [2] .
Raderer observed 16 instances of dyspnoea among 87 patients treated with vinorelbine (18%), four of which were grade I, six grade II, and six grade III-IV [1] .
Our data are in accord with these reports, and the pathogenetic hypothesis suggested by Hohneker might also explain our findings.
Hohneker distinguished between two types of vinorelbinerelated respiratory reactions: an acute reaction resembling an allergic reaction, and a subacute reaction, probably due to acute endothelium-alveolar damage.
We believe that an acute drug-induced endothelium-alveolar trauma could be the first event in the respiratory distress observed in our patients.
Considering that acute dyspnoea occurred after multiple administrations of vinorelbine in five of six cases, an allergic event seems unlikely, though it cannot be excluded.
Moreover, chest X-rays carried out during the course of the acute reactions yield a picture suggestive of acute endothelium-alveolar damage.
We believe that acute grade IV dyspnoea is a side effect, though an infrequent one, of vinorelbine.
On the other hand, since vinorelbine is largely used in advanced non-small-cell lung cancer or advanced pre-treated breast cancer, it is difficult to determine whether mild or moderate symptoms characterizing grade I-II dyspnoea are due to cytotoxic therapy or to the underlying disease. 
